PMID- 20041474
OWN - NLM
STAT- MEDLINE
DCOM- 20100301
LR  - 20131121
IS  - 1099-1077 (Electronic)
IS  - 0885-6222 (Linking)
VI  - 25
IP  - 1
DP  - 2010 Jan
TI  - Switching stable patients with schizophrenia from depot and oral antipsychotics 
      to long-acting injectable risperidone: reasons for switching and safety.
PG  - 37-46
LID - 10.1002/hup.1085 [doi]
AB  - OBJECTIVE: An international, non-randomised study evaluated efficacy and safety 
      of risperidone long-acting injectable (RLAI) compared to previous treatment. To 
      investigate generizability of the European data set to the UK subset safety and 
      switching data are reported here. METHODS: Patients with schizophrenia or other 
      psychotic disorder, symptomatically stable on antipsychotic medication, received 
      intramuscular injections of RLAI 25 mg (to a maximum of 50 mg) every 2 weeks for 
      6 months. RESULTS: Of 182 UK patients enrolled, 79% had schizophrenia, 21% other 
      psychotic disorders. Insufficient efficacy (43%), side effects (45%), and 
      non-compliance (25%) were the most common reasons for switching. Sixty-nine per 
      cent of patients completed the trial; 8% discontinued due to adverse events 
      (AEs). Most frequent treatment-emergent AEs were headache (8.2%), relapse (7.7%) 
      and insomnia (7.1%); 8 (4.4%) patients reported injection-related AEs. There were 
      significant improvements in extrapyramidal symptom rating scale total and 
      subscale (particularly Parkinsonism) scores, regardless of previous medication 
      (total cohort, p < or = 0.0001). There was a small but significant increase in 
      body weight at endpoint (1.2 kg, p = 0.0023). One patient suffered a myocardial 
      infarction and died (not treatment-related). There were no substantial 
      differences between the full data set and the UK sub-population CONCLUSION: 
      Switch to RLAI was well-tolerated in stable patients over 6 months. The European 
      data set is generalizable to the UK patient population.
FAU - Hawley, Chris
AU  - Hawley C
AD  - Hertfordshire Partnership Foundation Trust, Queen Elizabeth Hospital, Howlands, 
      Welwyn Garden City, Hertfordshire, UK. C.1.Hawley@herts.ac.uk
FAU - Turner, Martin
AU  - Turner M
FAU - Latif, Muhammud A
AU  - Latif MA
FAU - Curtis, Vivienne
AU  - Curtis V
FAU - Saleem, Packeruther T
AU  - Saleem PT
FAU - Wilton, Kristina
AU  - Wilton K
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Hum Psychopharmacol
JT  - Human psychopharmacology
JID - 8702539
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - L6UH7ZF8HC (Risperidone)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Antipsychotic Agents/*administration & dosage/adverse effects
MH  - Delayed-Action Preparations/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Drug Delivery Systems
MH  - Female
MH  - Humans
MH  - Injections, Intramuscular/methods
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Psychiatric Status Rating Scales
MH  - Psychotic Disorders/*drug therapy
MH  - Risperidone/*administration & dosage/adverse effects
MH  - Schizophrenia/*drug therapy
MH  - Treatment Outcome
EDAT- 2009/12/31 06:00
MHDA- 2010/03/02 06:00
CRDT- 2009/12/31 06:00
PHST- 2009/12/31 06:00 [entrez]
PHST- 2009/12/31 06:00 [pubmed]
PHST- 2010/03/02 06:00 [medline]
AID - 10.1002/hup.1085 [doi]
PST - ppublish
SO  - Hum Psychopharmacol. 2010 Jan;25(1):37-46. doi: 10.1002/hup.1085.